Ophthotech Corporation (Nasdaq:OPHT) today provided an update on the Company’s business and announced financial results for the second quarter ended June 30, 2014.
Recent Highlights
•In May 2014, the Company entered into an ex-US licensing and commercialization agreement with Novartis Pharma AG focused on the treatment of wet age-related macular degeneration (AMD).
Help employers find you! Check out all the jobs and post your resume.
